Kornimate/medical-research-clean huggingface dataset:
action observation therapy in patients undetgoing surgery for shoulder instability

Conditions: Shoulder Instability

Summary: the study will aim at investigating the effects of action observation therapy (action observation plus motor imagery) in patients with shoulder instability undergoing capsulo-plastic surgery. forty subjects scheduled for capsulo-plastic surgery will be randomized into an aot or control group. aot group will undergo action observation followed by motor imagery of upper limb motor tasks for 4 weeks after surgery, whereas control group will perform no intervention. in addition, both groups will undergo postoperative usual care including immobilization with a brace and passive upper limb mobilization. all participants will be assessed for shoulder pain, function, range of motion, fear of movement and quality of life the day before surgery, at training end and 3 months after training end.


Eligibility criteria:
inclusion criteria: * subjects undergoing capsule-plastic surgery or latarjet stabilization for shoulder instability exclusion criteria: * previous upper limb surgery * cognitive impairments * visual or auditory impairments * postoperative complications limiting upper limb motor recovery (e.g., infections)
in-patient asthma counseling by pulmonologist and hospital re-admission rate

Conditions: Asthma

Summary: prospective randomized clinical trial to assess the effect of in-hospital intensive counseling and follow-up vs. usual care, on re-admission rates of patients with asthma. the study population will include asthma patients admitted to internal medicine departments and medical icu at soroka university medical center, due to asthma exacerbation.


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 18 years old. 2. admitted to internal medicine at soroka university medical center due to asthma exacerbation. exclusion criteria: 1. substance abuse (except for tobacco). 2. handicapped or bed ridden patients. 3. patients who don't speak hebrew, english, russian or arabic. 4. other significant respiratory disease such as copd, interstitial lung disease (as decided by the pi).
efficacy of injectable fentanyl in sublingual route versus oral morphine syrup for breakthrough pain

Conditions: Pain, Breakthrough

Summary: randomized control trial that to comparison the efficacy of injectable fentanyl in sublingual route versus oral morphine syrup for breakthrough pain in gynecologic cancer patients with chronic cancer pain primary outcome : to measure pain score after drug is given

objective; to comparison the efficacy of injectable fentanyl in sublingual route versus oral morphine syrup for breakthrough pain in gynecologic cancer patients with chronic cancer pain population : gynecologic cancer patients with chronic cancer pain that use opioid drug for basal pain and had experienced of breakthrough pain cancer in rajavithi hospital sample size : 20 person/group method ; randomized control trial , prospective intervention : group a : injectable fentanyl in sublingual , group b : oral morphine syrup primary outcome : to measure pain score after drug is given at 5, 15, 30, 45, 60 and 120 min secondary outcome : to record side effect of drug is given at 5, 15, 30, 45, 60 and 120 min statistical method * categorical data = chi-square test or fishers' exact test * continuous data : comparison with student t-test in normal deviation data and man-whitney u- test in abnormal deviation data • analytical data with pearson's correlation, linear regression or binary logistic regression, repeated measures anova with or (95%ci) and p-value \<0.05

Eligibility criteria:
inclusion criteria: * gynecologic cancer patients with chronic cancer pain that use opioid drug for basal pain exclusion criteria: * allergy in fentanyl or morphine * abnormal cognitive function patient

Keywords: breakthrough pain injectable fentanyl in sublingual route gynecologic cancer
cerebral hemodynamics in sleep disorders

Conditions: Sleep Disorders, Intrinsic

Summary: the purpose of this study is to determine the relationship between sleep disorders and cerebral hemodynamics.

sleep disorders continue to be the most unrecognized modifiable risk factor for stroke. the relationship between sleep disorders and vascular risk factors and stroke has been well-documented but not fully understood. the investigators hypothesize hemodynamics impairment to be its potential mechanism. it has been reported that sleep-related breathing disorder, a type of sleep disorders, contributed as a risk factor for stroke through hemodynamic and hematologic changes. the purpose of this study is to determine the relationship between different kind of sleep disorders and cerebral hemodynamics, including oshas, rls, rbd, narcolepsy, etc. the dynamic cerebral auto-regulation (dca) and transcranial doppler (tcd) will be used to evaluate cerebral hemodynamics.

Eligibility criteria:
inclusion criteria: * patients with sleep disorders * meet the diagnostic criteria for sleep dyssomnias * sufficient bilateral temporal bone windows for insonation of the mca exclusion criteria: * middle cerebral artery (mca) and/or other intracranial and/or extracranial major vascular 4 stenosis/occlusion, as diagnosed by a transcranial doppler * having a prior symptomatic cerebral vascular disease * current arrhythmia, hyperthyroidism, anemia and unstable blood pressure, which may undermine hemodynamic stability * inability to cooperate sufficiently to complete the dca examination

Keywords: sleep disorders cerebral hemodynamics dynamic cerebral auto-regulation stroke
benefit of arterial preparation by longitudinal scoring

Conditions: Peripheral Arterial Disease

Summary: the purpose of the artery preparation concept is to perform regular longitudinal micro-incisions on the inner side of the artery ("scoring") and therefore promote a regular expansion of atheroma by balloon inflation.


Eligibility criteria:
inclusion criteria: * patients ≥ 18-year-old, with symptomatic lower extremity occlusive arterial disease * rutherford class of symptom 2 to 5 * atheromatous ≥ 70 % stenosis or occlusion of sfa and/or pa * absence of \> 50% residual stenosis of the run-in vessels at the end of procedure * presence of at least one patent (no ≥ 50 % stenosis) run-off tibial or fibular vessel to the foot at the end of procedure * de novo or restenotic lesions, including in-stent restenosis * willingness to participate in the study and signature of informed consent exclusion criteria: * renal failure with glomerular filtration rate (gfr) 30 ml/min or below, estimated by the cockroft-gault equation. * women who are pregnant, lactating, or planning to become pregnant during the duration of the study * recent artery thrombosis, at risk of distal embolization during percutaneous procedure * previous use of a pcb in the lesion during last 15 months * extremely calcified lesions, defined by calcification involving ³ 270° of the artery circumference over ³ 15 cm. * sub-intimal recanalization * tortuous contra-lateral femoral access with difficult cross-over * previous or planned surgery of the target lesion * high risk of bleeding * contra-indication to dual antiplatelet therapy for one month, and/or to single antiplatelet therapy for 1 year * allergy to aspirin, clopidogrel or heparin * life expectancy less than one year
clinical trial to determine the effectiveness and safety of topical insulin in dry eye

Conditions: Dry Eye; Insulin

Summary: this is a parallel randomized controlled trial for the treatment of dry eye disease. the main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. topical insulin drops will be compared to the current gold standard treatment, cyclosporin and placebo (artificial tears).

patients will be recruited in madrid. patients with dry eye disease and no topical treatment other than artificial tears will be identified through the ophthalmology clinic. they will be directly referred to a physician who is participating in this study.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * dry eye disease diagnosis * treatment with artificial tears or hyaluronic acid gels for at least 3 months * signed informed consent by the patient * staining equal to or greater than oxford ii exclusion criteria: * under 18 years old * corneal staining under oxford ii * treatment for dry eye disease other than artificial tears or hyaluronic acid gels * severe dry eye disease that requires immediate treatment * eye surgery in the last 6 months * other concomitant corneal pathology, eyelid malpositions, nasolacrimal drainage abnormalities, blinking alterations * contact lenses * other treatment besides artificial tears or hyaluronic acid gels * visual acuity less than 0.1 * allergy or intolerance to any of the components included in the study * modifications in systemic immunosuppressive treatment * pregnancy or lactation * women of childbearing age who do not use a highly effective contraceptive method * history of alcohol or drug abuse * participation in another clinical trial in the last 30 days * systemic pathology (cardiopulmonary pathology, connective tissue disorders, neurological or psychiatric pathology) or baseline situation of the patient that does not allow the examination (such as mental or psychomotor retardation)
oral mucosal pressure injury in icu patients with oral tracheal intubation

Conditions: Oral Mucosal Pressure Injury

Summary: in this study, based on the conceptual framework of pressure injurie development, the risk factors for pressure injury in critically ill patients provided by the latest guidelines, and combined with the current relevant studies on mucosal pressure injury, we prospectively observed and collected clinical data related to tracheal intubation patients in the icu, analyzed the risk factors for the occurrence of oral mpi, and established a risk prediction model to help clinical and nursing staff to detect and actively prevent oral mpi at an early stage the study aims to improve the quality of nursing management, enhance the level of nursing services and improve patient satisfaction.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. duration of icu admission ≥ 48h. exclusion criteria: 1. radiotherapy oral mucositis; 2. pressure injury to the mucosa, oral ulcers and erosions from other causes already present prior to tracheal intubation; 3. patients undergoing oral surgery; 4. those who have been brought in from outside the hospital for \>48h for transoral tracheal intubation; 5. common oral ulcers (not pressure/friction generated).

Keywords: intensive care units intubation, intratracheal mucosal pressure injury prediction model
a study of shr-1701 plus platinum-containing chemotherapy with or without bp102 (bevacizumab) as first-line treatment in cervical cancer

Conditions: Cervical Cancer

Summary: the study is being conducted to evaluate the efficacy, and safety of shr-1701 or placebo plus chemotherapy with or without bp102 (bevacizumab) as first-line treatment in patients with persistent, recurrent, or metastatic cervical cancer.


Eligibility criteria:
inclusion criteria: 1. aged 18-70 years, female. 2. with eastern cooperative oncology group (ecog) performance status scores of 0-1. 3. with a life expectancy of ≥ 12 weeks. 4. acute toxicities from prior anti-tumor treatments must have resolved to grade 0-1 (per nci ctcae 5.0). 5. with at least one measurable lesion as per recist v1.1. 6. with histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix. 7. persistent, recurrent, or metastatic cervical cancer. 8. patients to be enrolled in stage ii are required to provide a minimum of 10 slides of fresh (preferred). 9. women of childbearing potential must have a negative serum pregnancy test within 3 days prior to starting study treatment. 10. patients must agree and have signed the informed consent form. exclusion criteria: 1. with known contraindications to paclitaxel, cisplatin, or carboplatin. 2. with known allergies to any of the study drugs or their excipients; severe allergic reactions to other monoclonal antibodies. 3. with inadequately treated cns metastasis. 4. with uncontrolled hypertension. 5. with uncontrolled cardiac diseases or symptoms. 6. with major vascular disease. 7. with arterial/venous thrombotic events within 6 months prior to randomization. 8. have received full-dose anticoagulant or hemolytic therapy within 10 days prior to randomization. 9. with clinically significant hemorrhage or definitive bleeding diathesis within 3 months prior to randomization. 10. with severe, unhealed, or open wounds as well as active ulcers or untreated fractures. 11. with any active autoimmune disease or a history of autoimmune disease that is expected to recur. 12. had other active malignant tumors within 5 years prior to study enrolment. 13. with congenital or acquired immunodeficiency (such as hiv-infected patients).
multicenter study to evaluate safety and efficacy of wc3011 (estradiol vaginal cream) in postmenopausal women

Conditions: Vulvovaginal Atrophy

Summary: the primary objective of this study is to compare the efficacy of wc3011 with placebo vaginal gel in postmenopausal women for the relief of vaginal dryness caused by vaginal atrophy as measured by self-assessment, vaginal ph and vaginal smear.


Eligibility criteria:
inclusion criteria: * signed informed consent * moderate to severe vaginal dryness * postmenopausal meeting one of the following: 12 months spontaneous amenorrhea, 6 months spontaneous amenorrhea with serum follicle-stimulating hormone (fsh) \> 40 milli-international unit (miu)/ml, 6 weeks postsurgical bilateral oophorectomy confirmed by surgical report, ultrasound or serum fsh \> 40 miu/ml, 6 weeks postsurgical hysterectomy with ovary failure confirmed by serum fsh \> 40 miu/ml * age ≥ 40 years or if bilateral oophorectomy ≥ 35 years * vaginal ph \>5.0 * less than or equal 5% superficial cells on vaginal wall cytologic smear * normal breast exam; if \> 40 years, documentation of negative mammogram exclusion criteria: * randomization in pr-04409, participation in clinical trial or use of investigational drug within 30 days prior to screening * smokes ≥ 15 cigarettes/day * known or suspected premalignant or malignant disease * cardiovascular disease, insulin-dependent diabetes mellitus, congestive heart failure, stroke or ischemic attack, thrombophlebitis or thromboembolic disorder * increased frequency/severity headaches with estrogen therapy * drug addiction/alcohol abuse within last 2 years * currently taking st. john's wort or anticoagulant * uncontrolled hypertension or thyroid disorder, clinically significant depression or untreated urinary tract infection

Keywords: vaginal dryness vaginal atrophy estrogen
reproducibility of acute caffeine effect

Conditions: Caffeine and Resistance Exercise

Summary: introduction: various studies have evaluated and verified the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. however, all experimental investigations designed so far have been based on the comparison of the \&#34;caffeine\&#34; and \&#34;placebo\&#34; conditions in a single trial, not considering the reproducibility and variability of caffeine in multiple trials. objectives: the present study aims to evaluate the reproducibility and replicability of the acute effect of caffeine intake on energy metabolism and the muscular production of force, power and endurance, according to sex (men vs women) and type of exercise ( bench press vs squat).


Eligibility criteria:
inclusion criteria: * age between ≥ 18 and ≤ 35 years. * body mass index (bmi) \&lt; 25 kg/m². * resistance-trained individuals (\&gt; 2 years of structured trained). * healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising. * participants must be able to perform the tests described in the following section. exclusion criteria: * history of neuromuscular diseases, heart diseases, or diseases that may affect liver or muscle metabolism. * use of drugs, other stimulants or sport supplements that interfere with the the study dietary supplement. * sedentary habits (\&lt;150 min/week of moderate exercise). * having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. * performing strenuous exercise during the 48 hours prior to the tests. * failure to replicate the same food intake on the two days of the experiments. * consuming caffeine or any other stimulant after 6 pm the day before the training or tests, to avoid headaches, discomfort, or lethargy among regular caffeine consumers.
evaluation of d-fi for the treatment of wounds due to deb

Conditions: Dystrophic Epidermolysis Bullosa

Summary: the purpose of this study is to determine whether administration of d-fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with dystrophic epidermolysis bullosa.

ccb-eb-304 is a multi-center, intra-patient randomized and controlled, open-label, rater-blinded phase 3 study of d-fi for the treatment of persistent non-healing and recurrent deb wounds in approximately 32 subjects. each subject will serve as his/her own control. each subject's target wounds will be paired then randomized to receive d-fi (treatment wound) or remain untreated (control wound). one target wound pair will be identified for each subject. subjects will receive intradermal injections of d-fi in each specified treatment wound in three or more treatment sessions. the first treatment session occurs at day 1, the second at week 8/month 2 and the third at week 16/month 4. additional treatment sessions may occur at week 26/month 6 and week 32/month 8 and week 40/month 10 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated. safety and efficacy assessments will occur at scheduled intervals through week 48/month 12, when the treatment period is completed, and a long-term safety follow-up period (through 15 years) commences for subjects who have received one or more d-fi injections.

Eligibility criteria:
inclusion criteria: * male or female ≥2 years of age at the screening visit * clinical diagnosis of deb with confirmation of col7a1 genetic mutation. exclusion criteria: * medical instability limiting ability to travel to the investigative site. * active infection with human immunodeficiency virus, hepatitis b or hepatitis c. * the presence of col7 antibodies. * evidence of systemic infection. * known allergy to any of the constituents of the product. * female who is pregnant or breastfeeding.

Keywords: deb
adjuvant chemotherapy with s-1 plus oxaliplatin versus s-1 alone in locally advanced gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of the study is to evaluate the efficacy and safety of s-1 plus oxaliplatin versus s-1 only as adjuvant chemotherapy after curative distal gastrectomy in patients with locally advanced gastric cancer.

the study is a multi-central, controlled, randomized phase iii trial. the protocol has been approved by the ethics committee of beijing cancer hospital. the primary endpoint is the 3-year progression-free survival (pfs) rate. the secondary endpoints are the overall survival (os) and safety.

Eligibility criteria:
inclusion criteria: * sign written informed consent form * age ≥ 18 years, ≤69 years * ecog status: 0\~2 * pathologically confirmed gastric cancer at stage ii or iiia (ajcc 7th version) * negative peritoneal cytology * underwent curative distal gastrectomy with d2 lymph node dissection * no prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy * adequate organ function as defined below: hematologic anc ≥ 2\*109/l, platelets ≥ 100\*109/l, ast and alt ≤ 2.5×uln, tbil ≤ 1.5×uln. exclusion criteria: * be enrolled in other clinical trials * underwent prior antitumor treatment * allergic reaction to s-1 or oxaliplatin * abnormal gi tract function * female in pregnancy or lactation, or refuse to receive contraception measures during chemotherapy * other situation to be judged not adaptive to the study by investigators

Keywords: gastric cancer adjuvant chemotherapy s1 oxaliplatin survival
home transfusion for heme

Conditions: Hematologic Malignancy

Summary: the purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions

this feasibility study will be used to assess the feasibility and acceptability of a hospice-embedded home transfusion program to patients with hematologic malignancies. all enrolled subjects will be patients cared for at dana farber cancer institute. this study is a single-arm study of 10 patients with advanced hematologic malignancies who have a limited life-expectancy of six months or fewer and are hospice eligible. 10 caregivers of enrolled patients will also be invited to participate if interested. this research study involves completing questionnaires, a brief interview, blood draws, and blood transfusions when needed. participants will be in the research study for up to six months. it is expected that about 20 people will take part in this research study.

Eligibility criteria:
inclusion criteria: * patients with advanced hematologic malignancies: * diagnosis of a hematologic malignancy * age ≥ 18 years * receipt of primary oncologic care at dfci (at least 2 outpatient visits in 12 months prior to enrollment) * has received at least one red blood cell (rbc) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a serious adverse transfusion reaction * physician-estimated prognosis of six months or less * has an adult informal caregiver that lives in the same residence * patient resides within catchment served by care dimensions hospice * caregivers: * identified informal caregiver of enrolled patient with hematologic malignancy * age ≥ 18 years exclusion criteria: * patients * age \< 18 years * does not have an identified adult informal caregiver who lives in the same residence * history of previous serious adverse transfusion reaction * presence of decompensated congestive heart failure * caregiver * age \< 18 years * our study will exclude members of the following special populations: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners

Keywords: hematologic malignancy
cerebral autoregulation in pediatric ecmo (ecmox 2)

Conditions: Acute Respiratory Distress Syndrome (ARDS); Cardiogenic Shock; Cardiac Arrest

Summary: children supported by extra-corporeal membrane oxygenation (ecmo) present a high risk of neurological complications and cerebral autoregulation (ca) impairment may be a risk factor. the first objective is to investigate the association between ca impairments and neurological outcome assessed by the onset of an ane. the secondary objective is to study the underlying mechanisms influencing ca.

patients : all children treated by ecmo in the 4 picus involved in the study measurements : a correlation coefficient between the variations of regional cerebral oxygen saturation (rsco2) as a surrogate of cerebral blood flow and the variations of arterial blood pressure (abp) is calculated as an index of autoregulation (cerebral oxygenation index (cox), icm+ software®). ca is monitored either on left (coxl) or both sides. a cox \> 0.3 is considered as critical. neurological outcome is assessed by the onset of an acute neurologic event (ane) during the ecmo run.

Eligibility criteria:
inclusion criteria : * patients under the age of 18 years treated by ecmo exclusion criteria : * lack of parental consent

Keywords: ecmo cerebral autoregulation